We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
With Drug-loaded Nanogel, Yale Researchers Attack Cancerous Tumors
News

With Drug-loaded Nanogel, Yale Researchers Attack Cancerous Tumors

With Drug-loaded Nanogel, Yale Researchers Attack Cancerous Tumors
News

With Drug-loaded Nanogel, Yale Researchers Attack Cancerous Tumors

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "With Drug-loaded Nanogel, Yale Researchers Attack Cancerous Tumors"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

“We believe this is a paradigm-changing immunotherapeutic method for cancer therapy,” said Tarek M. Fahmy, a bioengineer at Yale and the project’s principal investigator. “In essence, it’s a one-two punch strategy that seems to work well for melanoma and may work even better with other cancers.”

The researchers report results July 15 online in the journal Nature Materials. Dr. Richard A. Flavell of Yale School of Medicine and the Howard Hughes Medical Institute collaborated on the project.

Tumors — in this case metastatic melanomas, or spreading skin cancers — are adept at overcoming their host’s natural defenses, in part by emitting agents that disrupt production and operation of the immune system.

The Yale team developed a new biodegradable nanoparticle that delivers a combination of two very different therapeutic agents to tumor sites, gradually releasing the agents into the tumor vasculature. One agent, a large soluble protein called a cytokine, stimulates the body’s innate immune response. The other, a small-molecule inhibitor, interferes with the tumor’s ability to suppress the immune response. Other drug combinations are possible.

In tests on live mice, the double-loaded particle, called a nanogel, significantly delayed tumor growth and increased survival, the researchers report. They administered the nanogels intravenously and, in separate experiments, directly into the tumors.  Further animal tests are planned.

The main challenge researchers faced was devising a particle that enabled gradual, sustained release of two therapeutic agents with very different properties: the protein, which readily dissolves in the body, and the small-molecule drug, which doesn’t. Researchers describe the materials and unique structure of their solution in the Nature Materials paper.

They exclusively used components already approved by the U.S. Food and Drug Administration. This could potentially expedite future experiments with other ingredients and human trials, they said.

Advertisement